Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26040
Title: Towards a Universal Readout for Fluorine-18 Labelled Amyloid Tracers: The CAPTAINs Study.
Austin Authors: Bischof, Gerard N;Bartenstein, Peter;Barthel, Henryk;van Berckel, Bart N M;Doré, Vincent ;van Eimeren, Thilo;Foster, Norman L;Hammes, Jochen L;Lammertsma, Adriaan A;Minoshima, Satoshi;Rowe, Christopher C ;Sabri, Osama;Seibyl, John;van Laere, Koen;Vandenberghe, Rik;Villemagne, Victor L ;Yakushev, Igor;Drzezga, Alexander E
Affiliation: Nuclear Medicine and Molecular Imaging, University Hospital Leuven and Department of Imaging and Pathology KU Leuven, Leuven, Belgium
Department of Nuclear Medicine, Technical University of Munich, Germany
University Hospital of Leipzig, Department of Nuclear Medicine, Leipzig, Germany
University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne, Germany
University Hospital of Leipzig, Department of Nuclear Medicine, Leipzig,, Germany
Department of Nuclear Medicine, LMU Munich, Germany
University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne,, Germany
Memory Clinic, University Hospital Leuven and Department of Neurosciences, KU Leuven, Belgium
Amsterdam University Medical Centers, Location VUmc Radiology and Nuclear Medicine, Amsterdam, Netherlands..
CSIRO Health and Biosecurity
University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne & Department of Neurology, University Hospital Cologne, Cologne & German Center of Neurodegenerative Disease (DZNE)..
Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, United States..
Amsterdam University Medical Centers, Location VUmc Radiology and Nuclear Medicine, Amsterdam, Netherlands..
Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, United States..
CSIRO Health and Biosecurity & Department of Molecular Imaging & Therapy, Austin Health, Melbourne..
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States..
CSIRO Health and Biosecurity & Department of Molecular Imaging & Therapy, Austin Health, Melbourne..
University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne & German Center of Neurodegenerative Disease (DZNE)..
Molecular Imaging and Therapy
Issue Date: 12-Mar-2021
metadata.dc.date: 2021
Publication information: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2021; online first: 12 March
Abstract: To date, three fluorine-18 labelled tracers have been approved for assessing cerebral amyloid plaques pathology to assist in the diagnosis of Alzheimer's Disease (AD). Although scanning protocols are relatively similar across tracers, FDA/EMA approved visual rating guidelines to render scans as positive or negative differ between the three tracers. The purpose of the present study was to assess the comparability of visual rating results when applying the three different FDA/EMA approved visual interpretation protocols to all three amyloid tracers both for experts and non-experts. Methods: In an international multicentre approach, both experts (N = 4) and non-experts (N = 3) rated scans acquired with fluorine-18 labelled florbetaben, florbetapir and flutemetamol. Scans obtained with each tracer were presented for reading according to all three approved visual rating protocols. In a randomized order, every single scan was rated by each reader according to all three protocols, resulting in a total of more than 700 image ratings. Raters were blinded for the amyloid tracer used and asked to rate each scan as positive or negative, giving a confidence judgement after each response. Percentage of visual reader agreement, inter-rater reliability and agreement of each visual read with binary quantitative measures of standard uptake value ratio based on a fixed threshold for positive and negative scans were computed. These metrics were analyzed separately for expert and non-expert groups. Results: No significant differences in visual ratings across the different metrics of agreement were observed in the group of experts. Nominal differences suggested that the Florbetaben visual rating protocol achieved the highest interrater reliability and accuracy especially under low confidence conditions. For the group of non-experts significant differences in visual ratings were observed with overall moderate-to-fair accuracy and with the highest reliability for the Florbetapir visual rating procedure. Conclusion: We observed high interrater agreement despite applying different visual rating protocols for all fluorine-18 labelled amyloid tracers, suggesting sufficient potiential for a standardization for visual assessment of cerebral amyloid plaques. Non-experts, however, may need extensive training on reading fluorine-18 labelled amyloid scans and may particularly benefit from a universal readout to ensure comparability across visual evaluation strategies.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26040
DOI: 10.2967/jnumed.120.250290
PubMed URL: 33712532
Type: Journal Article
Subjects: Amyloid PET
Florbetaben
Florbetapir
Flutemetamol
Molecular Imaging
Neurology
PET
Visual reading standardization
Appears in Collections:Journal articles

Show full item record

Page view(s)

20
checked on May 15, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.